THE PRESENCE OF DYSPLASTIC NEVUS REMNANTS IN MALIGNANT MELANOMAS - A POPULATION-BASED STUDY OF 551 MALIGNANT MELANOMAS

被引:32
|
作者
HASTRUP, N
OSTERLIND, A
DRZEWIECKI, KT
HOUJENSEN, K
机构
[1] UNIV COPENHAGEN,RIGSHOSP,DEPT PATHOL,DK-2100 COPENHAGEN,DENMARK
[2] UNIV COPENHAGEN,RIGSHOSP,DEPT PLAST SURG,DK-2100 COPENHAGEN,DENMARK
[3] DANISH CANC SOC,INST CANC EPIDEMIOL,DANISH CANCER REGISTRY,COPENHAGEN,DENMARK
关键词
DYSPLASTIC NEVUS; MALIGNANT MELANOMA; HISTOPATHOLOGY;
D O I
10.1097/00000372-199108000-00009
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
We examined 512 malignant melanomas, representing all newly diagnosed cutaneous malignant melanomas, excluding lentigo maligna melanomas, from the period October 1, 1982 to March 31, 1985 occurring in the region of eastern Denmark in patients aged 20-79 years for the presence of dysplastic nevus remnants. Criteria for the diagnosis of a dysplastic nevus remnant include all the following changes (a) lentiginous or epithelioid melanocyte hyperplasia, (b) cytologic melanocyte atypia, (c) eosinophilic fibroplasia, (d) lamellar fibroplasia, and (e) lymphocytic infiltration in the dermis. Dysplastic nevus remnants were found in association with 34 (7%) of the evaluable 512 malignant melanomas. Fourteen (41%) of the remnants were of compound nevus type. In nine (27%) of the remnants, atypia was pronounced. Most (62%) dysplastic nevus remnants were contiguous to thin superficial spreading melanomas. We conclude from this population-based study that about 7% of malignant melanomas arise in prior dysplastic nevi.
引用
收藏
页码:378 / 385
页数:8
相关论文
共 38 条
  • [1] 2 SUPERFICIAL SPREADING MALIGNANT MELANOMAS ARISING FROM A NEVUS-SPILUS
    KRAHN, G
    THOMA, E
    PETER, RU
    HAUTARZT, 1992, 43 (01): : 32 - 34
  • [2] Immunohistochemical expression of VEGF, HIF1-a, and PlGF in malignant melanomas and dysplastic nevi
    Konstantina, Anagnostopoulou
    Lazaris, Andreas C.
    Ioannidis, Eleftherios
    Liossi, Anna
    Aroni, Kyriaki
    MELANOMA RESEARCH, 2011, 21 (05) : 389 - 394
  • [3] A COMPARATIVE-STUDY OF PROLIFERATION INDEXES AND PLOIDY IN DYSPLASTIC NEVI AND MALIGNANT MELANOMAS USING FLOW-CYTOMETRY
    SLATER, SD
    COOK, MG
    FISHER, C
    WRIGHT, NAW
    FOSTER, CS
    HISTOPATHOLOGY, 1991, 19 (04) : 337 - 344
  • [4] MELANOBLASTOMA DISEASE IN LABORATORY MINIPIGS - A MODEL FOR STUDY OF HUMAN-MALIGNANT MELANOMAS
    FORTYN, K
    HRUBAN, V
    HORAK, V
    HRADECKY, J
    TICHY, J
    VETERINARNI MEDICINA, 1994, 39 (10) : 597 - 604
  • [5] Different Patterns of Expression of the erbB Family of Receptor Tyrosine Kinases in Common Nevi, Dysplastic Nevi, and Primary Malignant Melanomas: An Immunohistochemical Study
    Feinmesser, Meora
    Veltman, Vladimir
    Morgenstern, Sara
    Tobar, Ana
    Gutman, Haim
    Kaganovsky, Ella
    Tzabari, Cohava
    Sulkes, Jaqueline
    Okon, Elimelech
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2010, 32 (07) : 665 - 675
  • [6] Primary Malignant Melanoma of the Brain: A Population-Based Study
    Puyana, Carolina
    Denyer, Steven
    Burch, Taylor
    Bhimani, Abhiraj D.
    McGuire, Laura S.
    Patel, Akash S.
    Mehta, Ankit, I
    WORLD NEUROSURGERY, 2019, 130 : E1091 - E1097
  • [7] Epidemiology and survival outcomes of ocular and mucosal melanomas: A population-based analysis
    Bishop, Kenneth D.
    Olszewski, Adam J.
    INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (12) : 2961 - 2971
  • [8] Immunohistochemical expression of matrix metalloproteinase-2 (MMP-2) in common melanocytic nevi, dysplastic nevi and primary cutaneous malignant melanomas
    Lebe, Banu
    Pabuccuoglu, Ugur
    Ozer, Erdener
    TURKISH JOURNAL OF PATHOLOGY, 2006, 22 (02) : 82 - 86
  • [9] New malignancies after squamous cell carcinoma and melanomas: a population-based study from Norway
    Trude E Robsahm
    Margaret R Karagas
    Judy R Rees
    Astri Syse
    BMC Cancer, 14
  • [10] Diffuse malignant melanomas of the uvea. A clinico-pathologic study of 39 patients
    Braun, UC
    Rummelt, VC
    Naumann, GO
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 1998, 213 (06) : 331 - 340